Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan

被引：1

作者：

Liu, Hsi-Che ^{[1
]}

Kuo, Ming-Chung ^{[2
,3
]}

Wu, Kang-Hsi ^{[4
]}

Chen, Tsai-Yun ^{[5
]}

Chen, Jiann-Shiuh ^{[6
]}

Wang, Ming-Chung ^{[7
]}

Lin, Tung-Liang ^{[2
]}

Yang, YoungSen ^{[8
,9
]}

Ma, Ming-Chun ^{[7
]}

Wang, Po-Nan ^{[2
]}

Sheen, Jiunn-Ming ^{[10
,11
]}

Wang, Shih-Chung ^{[12
]}

Chen, Shih-Hsiang ^{[13
]}

Jaing, Tang-Her ^{[13
]}

Cheng, Chao-Neng ^{[6
]}

Yeh, Ting-Chi ^{[1
]}

Lin, Tung-Huei ^{[2
]}

Shih, Lee-Yung ^{[2
,3
]}

机构：

[1] MacKay Childrens Hosp, MacKay Med Coll, Dept Hematol Oncol, Taipei, Taiwan

[2] Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Linkou, Taoyuan, Taiwan

[3] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[4] Chung Shan Med Univ Hosp, Dept Pediat, Taichung, Taiwan

[5] Natl Cheng Kung Univ Hosp, Div Hematol Oncol, Tainan, Taiwan

[6] Natl Cheng Kung Univ Hosp, Dept Pediat, Tainan, Taiwan

[7] Chang Gung Mem Hosp Kaohsiung, Div Hematol Oncol, Kaohsiung, Taiwan

[8] Taichung Vet Gen Hosp, Dept Internal Med, Div Hematol Oncol, Taichung, Taiwan

[9] China Med Univ, Coll Med, Internal Med, Taichung, Taiwan

[10] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Dept Pediat, Kaohsiung, Taiwan

[11] Chiayi Chang Gung Mem Hosp, Dept Pediat, Chiayi, Taiwan

[12] Changhua Christian Childrens Hosp, Div Pediat Hematol Oncol, Changhua, Taiwan

[13] Chang Gung Univ, Chang Gung Childrens Hosp Linkou, Dept Hematol Oncol, Taoyuan, Taiwan

来源：

BRITISH JOURNAL OF CANCER | 2023年 / 128卷 / 07期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; LONG-TERM SURVIVAL; CHRONIC PHASE; PROGNOSTIC DISCRIMINATION; CYTOGENETIC RESPONSE; 1ST-LINE TREATMENT; DOSE IMATINIB; SINGLE-CENTER; YOUNG-ADULTS;

D O I：

10.1038/s41416-023-02162-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The direct comparison of molecular responses of front-line imatinib (IM) monitored at the same laboratory between children and adults with chronic phase (CP) of chronic myeloid leukaemia (CML) had not been reported. In this multicenter study, we compared the landmark molecular responses and outcomes of paediatric and adult CML-CP cohorts treated with front-line IM in whom the BCR::ABL1 transcript levels were monitored at the same accredited laboratory in Taiwan. Methods: Between June 2004 and July 2020, 55 newly diagnosed paediatric and 782 adult CML-CP patients, with molecular diagnosis and monitoring at the same reference laboratory in Taiwan, were enrolled. The criteria of 2020 European LeukemiaNet were applied to evaluate the molecular responses. Results: By year 5, the cumulative incidences of IS <1%, MMR, MR4.0 and MR4.5 of paediatric patients were all significantly lower than those of adult patients (58 vs 75%, 48 vs 66%, 25 vs 44%, 16 vs 34%, respectively). The 10-year progression-free survival (PFS) (90%) and overall survival (OS) (94%) of paediatric patients did not differ from those (92%) of adult patients. Conclusions: We demonstrated the paediatric cohort had slower molecular responses to front-line IM and similar outcomes in 10-year PFS and OS in real-world practice.

引用

页码：1294 / 1300

页数：7

共 1 条

[1] Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Yhim, Ho-Young
Lee, Na-Ri
Song, Eun-Kee
Yim, Chang-Yeol
Jeon, So Yeon
Shin, Seunghwan
Kim, Jeong-A
Kim, Hee Sun
Cho, Eun Hae
Kwak, Jae-Yong
LEUKEMIA RESEARCH, 2012, 36 (06) : 689 - 693

← 1 →